Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.

Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D

Obesity (Silver Spring, Md.)1 Mar 2020Cited by 154 (Europe PMC)

PMID32090517PMCIDPMC7065111DOI10.1002/oby.22726PepBankPUB-32090517

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity in primary care, liraglutide 3.0 mg plus behavioral therapy produced more weight loss than placebo plus behavioral therapy at week 56.
In plain wordsIn adults with obesity, liraglutide 3.0 mg with behavioral therapy led to more weight loss than placebo with behavioral therapy.
Peptide
Liraglutide
Outcome
DecreaseMean weight loss at week 56
Study
n = 282
Comparator
Placebo (both arms with intensive behavioral therapy)
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Mean weight loss
7.5%
liraglutide 3.0 mg plus IBT
Mean weight loss
4%
placebo plus IBT
Source sentences
Summary
At week 56, mean weight loss with liraglutide 3.0 mg plus IBT was 7.5% and 4.0% with placebo combined with IBT (estimated treatment difference [95% CI]-3.4% [-5.3% to -1.6%], P = 0.0003).
1 context sentence(design, population, supporting numbers)
Summary · context
The Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) IBT was a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140) as an adjunct to IBT.
Report a problemFND-3209051701
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity in primary care, more people on liraglutide 3.0 mg than on placebo lost at least 5% of body weight.
In plain wordsIn adults with obesity, more people lost at least 5% of their weight with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of 5% or more
Study
n = 282
Comparator
Placebo (both arms with intensive behavioral therapy)
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Proportion with weight loss >=5%
61.5%
liraglutide 3.0 mg
Proportion with weight loss >=5%
38.8%
placebo
Source sentences
Summary
Significantly more individuals on liraglutide 3.0 mg than placebo achieved ≥ 5% weight loss (61.5% vs. 38.8%; odds ratio [OR] 2.5% [1.5% to 4.1%], P = 0.0003)
1 context sentence(design, population, supporting numbers)
Summary · context
The Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) IBT was a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140) as an adjunct to IBT.
Report a problemFND-3209051702
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity in primary care, more people on liraglutide 3.0 mg than on placebo lost more than 10% of body weight.
In plain wordsIn adults with obesity, more people lost over 10% of their weight with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of more than 10%
Study
n = 282
Comparator
Placebo (both arms with intensive behavioral therapy)
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Proportion with weight loss >10%
30.5%
liraglutide 3.0 mg
Proportion with weight loss >10%
19.8%
placebo
Source sentences
Summary
> 10% weight loss (30.5% vs. 19.8%; OR 1.8% [1.0% to 3.1%], P = 0.0469)
1 context sentence(design, population, supporting numbers)
Summary · context
The Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) IBT was a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140) as an adjunct to IBT.
Report a problemFND-3209051703
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity in primary care, more people on liraglutide 3.0 mg than on placebo lost more than 15% of body weight.
In plain wordsIn adults with obesity, more people lost over 15% of their weight with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseWeight loss of more than 15%
Study
n = 282
Comparator
Placebo (both arms with intensive behavioral therapy)
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Measurements
Proportion with weight loss >15%
18.1%
liraglutide 3.0 mg
Proportion with weight loss >15%
8.9%
placebo
Source sentences
Summary
> 15% weight loss (18.1% vs. 8.9%; OR 2.3% [1.1% to 4.7%], P = 0.0311)
1 context sentence(design, population, supporting numbers)
Summary · context
The Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) IBT was a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140) as an adjunct to IBT.
Report a problemFND-3209051704
05HumanRandomized controlled trialSafety outcome
In adults with obesity in primary care, liraglutide 3.0 mg with behavioral therapy was well tolerated and no new safety signals were identified.
In plain wordsIn adults with obesity, liraglutide 3.0 mg with behavioral therapy was well tolerated and showed no new safety signals.
Peptide
Liraglutide
Outcome
No significant changeOverall safety and tolerability
Study
n = 282
Comparator
Placebo (both arms with intensive behavioral therapy)
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg · 56 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide 3.0 mg in combination with IBT was well tolerated, with no new safety signals identified.
1 context sentence(design, population, supporting numbers)
Summary · context
The Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) IBT was a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in individuals with obesity who received liraglutide 3.0 mg (n = 142) or placebo (n = 140) as an adjunct to IBT.
Report a problemFND-3209051705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02963935

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Novo Nordisk A/Sn = 2826 Feb 2017 to 19 Jun 2018

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 11 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.